The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity

Volume: 12, Issue: 3, Pages: 564 - 564
Published: Feb 29, 2020
Abstract
The poly(ADP-ribose) polymerase (PARP) inhibitor, Rubraca®, was given its first accelerated approval for BRCA-mutated ovarian cancer by the FDA at the end of 2016, and further approval by the FDA, EMA and NICE followed. Scientists at Newcastle University initiated the early stages, and several collaborations with scientists in academia and the pharmaceutical industry enabled its final development to the approval stage. Although originally...
Paper Details
Title
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
Published Date
Feb 29, 2020
Journal
Volume
12
Issue
3
Pages
564 - 564
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.